SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

OLMA

Olema Oncology
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The EPS beat is modest and the wider loss is expected for a clinical-stage biotech. The real catalysts are the OPERA-01 top-line data (fall 2026) and OP-3136 ASCO data (late May/June). Monitor these events for binary outcomes that could move the stock 30-50%.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.97
T+0 close · May 12, 2026 · via day close
Latest settled
−15.53%
T+60 · $11.80
Vs SPY
−19.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $13.97entry
  2. T+1 · 6mo ago −2.79%α −3.37% · $13.58
  3. T+5 · 6mo ago −7.66%α −7.74% · $12.90
  4. T+20 · 5mo ago −29.71%α −27.98% · $9.82
  5. T+60 · 3mo ago −15.53%α −19.92% · $11.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Olema Oncology reported Q1 2026 EPS of -$0.52, a 7.2% beat vs consensus of -$0.54, but net loss widened to $53.1M from $30.4M a year ago due to increased R&D spending on late-stage trials. The stock is driven by upcoming catalysts: top-line Phase 3 OPERA-01 data expected fall 2026 and initial Phase 1 OP-3136 data at ASCO this month.

Key Financial Metrics

EPS
−$0.52
est −$0.54 · +3.7%
Rating
in line

Key Facts

  • Q1 2026 EPS -$0.52 vs consensus -$0.54 (7.2% beat)
  • Net loss $53.1M vs $30.4M YoY, driven by higher R&D spend
  • Cash position $505.3M as of March 31, 2026
  • Top-line Phase 3 OPERA-01 data expected fall 2026
  • Initial Phase 1 OP-3136 data to be presented at ASCO May/June 2026
  • Phase 3 OPERA-02 enrollment continuing

Financial Impact

Net loss increased 75% YoY to $53.1M; cash burn rate ~$53M/quarter

net lossR&D expensescash position

Risk Factors

  • Phase 3 OPERA-01 failure would be a severe negative catalyst
  • Cash burn rate implies ~2.5 years of runway; potential dilution risk
  • OP-3136 Phase 1 safety/efficacy data could disappoint

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292656

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026